ArticleOphthalmology and therapy2024
VIVEX: A Formula for Calculating Individual Vitreous Volume: A New Approach Towards Tailored Patient Dosing Regime in Intravitreal Therapy.
Article in Ophthalmology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 13 citations in OpenAlex.
- Extracellular vesicles as therapeutic agents for retinal ganglion cell degeneration: current challenges and future prospects.International ophthalmology · 2026Review
- Comparison of Clinical Outcomes of Intravitreal 0.625% Povidone-Iodine versus Antibiotic Injection for Postoperative Endophthalmitis.Korean journal of ophthalmology : KJO · 2026Article
- Trocar sleeve adapter accelerates silicone oil injection in real-world vitreoretinal surgery.Eye (London, England) · 2026Observational
- Geometry-Based Intravitreal Pharmacokinetics: A Theoretical Pharmacokinetic Modeling Study Using Triamcinolone Acetonide and Vancomycin as Representative Intravitreal Agents.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Real-World Validation of the VIVEX Formula for Vitreous Volume Estimation in Vitreoretinal Surgery: A First Clinical Case Series.Ophthalmology and therapy · 2026Article
- High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma.PloS one · 2026Article
- Ocular gene therapy as a sustained drug delivery system: pharmacokinetic and genokinetic perspectives.Journal of medicine and life · 2025Review
- Replacing the vitreous body with hydrogels: Rationale and strategies.Progress in retinal and eye research · 2025Review
- Performance of a Trocar Sleeve Adapter for Faster Silicone Oil Extraction in Real-World Vitreoretinal Surgery.Journal of clinical medicine · 2025Article
- Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis.Eye (London, England) · 2025Observational
- Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes after Intravitreal Anti-Vascular Endothelial Growth Factors Injection.Ophthalmic research · 2025Article
- Estimating the volume of the vitrectomized space using axial length: a guideline.Arquivos brasileiros de oftalmologia · 2025Observational
- Dose adjustment of intravitreal medications and gases according to axial length and vitreous cavity volume.Arquivos brasileiros de oftalmologia · 2025Article
- Letter to the Editor Regarding "VIVEX: A Formula for Calculating Individual Vitreous Volume: A New Approach Towards Tailored Patient Dosing Regime in Intravitreal Therapy".Ophthalmology and therapy · 2024Article
- A Response to: Letter to the Editor Regarding "VIVEX-A Formula for Calculating Individual Vitreous Volume: A New Approach Towards Tailored Patient Dosing Regime in Intravitreal Therapy".Ophthalmology and therapy · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPersonalized medicine and patient-tailored drug dosing have been substantiated through thousands of clinical studies, demonstrating their safety and efficacy. The principle: "as much as necessary, as little as possible" is widely spread. Quantities and doses are therefore adjusted individually. This is not the case for intravitreal injections in the context of retinal diseases. Intravitreal injections are not adjusted in relation to the vitreous volume. The vitreous body is described as "approx. 4 cm
methodsIn this retrospective observational study, we included 72 eyes of patients who had undergone magnetic resonance imaging (MRI) of the orbit and biometry measurements of the anterior chamber depth (ACD) and axial length. After segmentation of the volume data, the vitreous volume was extracted by voxel integration, and a simple prediction model was derived to determine the vitreous volume from the axial length (AL) measurement with AL
resultsEmmetropic eyes with an axial length of 22.50-23.50 mm had a vitreous volume of around 4.5-5.5 cm
conclusionsBy implementing the new calculation formula on the IOLCON website, it will be easy to get the exact individual vitreous volume. The data could be used by retinal surgeons prior to surgery. The knowledge of anatomical dimensions and exact individual vitreous volume seems to be important for gas and silicone oil fillings. With the newly derived knowledge, multicentric studies can evaluate the impact of the dose in intravitreal therapies. Patient-tailored dosing could prevent side effects and improve effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.